277 related articles for article (PubMed ID: 34001187)
1. Gene alterations as predictors of radiation-induced toxicity in head and neck squamous cell carcinoma.
Sumner W; Ray X; Sutton L; Rebibo D; Marincola F; Sanghvi P; Moiseenko V; Deichaite I
J Transl Med; 2021 May; 19(1):212. PubMed ID: 34001187
[TBL] [Abstract][Full Text] [Related]
2. Germline genetic biomarkers to stratify patients for personalized radiation treatment.
Deichaite I; Hopper A; Krockenberger L; Sears TJ; Sutton L; Ray X; Sharabi A; Navon A; Sanghvi P; Carter H; Moiseenko V
J Transl Med; 2022 Aug; 20(1):360. PubMed ID: 35962345
[TBL] [Abstract][Full Text] [Related]
3. Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes.
Romesser PB; Cahlon O; Scher ED; Hug EB; Sine K; DeSelm C; Fox JL; Mah D; Garg MK; Han-Chih Chang J; Lee NY
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):386-395. PubMed ID: 27084656
[TBL] [Abstract][Full Text] [Related]
4. Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study.
Deneuve S; Bastogne T; Duclos M; Mirjolet C; Bois P; Bachmann P; Nokovitch L; Roux PE; Girodet D; Poupart M; Zrounba P; Claude L; Ferella L; Iacovelli NA; Foray N; Rancati T; Pereira S
Tumori; 2023 Apr; 109(2):173-185. PubMed ID: 35578746
[TBL] [Abstract][Full Text] [Related]
5. Preliminary clinical outcomes of head and neck squamous cell carcinoma treated with particle beam radiation therapy.
Huang Q; Hu J; Hu W; Gao J; Yang J; Qiu X; Zhang H; Lu JJ; Kong L
Cancer Med; 2023 Jun; 12(11):12128-12138. PubMed ID: 37039275
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
7. Real-life assessment of Volumetric Modulated Arc Therapy (VMAT) toxicity in Head and Neck Squamous Cell Carcinoma (HNSCC) treatment.
Moncharmont C; Vallard A; Mengue Ndong S; Guy JB; Saget C; Méry B; Langrand-Escure J; de Laroche G; Goyet D; Prades JM; Fournel P; Magné N
Acta Otolaryngol; 2016; 136(2):181-8. PubMed ID: 26503806
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
[TBL] [Abstract][Full Text] [Related]
9. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
[TBL] [Abstract][Full Text] [Related]
10. Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia.
Yahya N; Linge A; Leger K; Maile T; Kemper M; Haim D; Jöhrens K; Troost EGC; Krause M; Löck S
Acta Oncol; 2022 Jul; 61(7):856-863. PubMed ID: 35657056
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
12. Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis.
Haussmann J; Tamaskovics B; Bölke E; Djiepmo-Njanang FJ; Kammers K; Corradini S; Hautmann M; Ghadjar P; Maas K; Schuler PJ; Hoffmann TK; Lammering G; Budach W; Matuschek C
Strahlenther Onkol; 2019 Dec; 195(12):1041-1049. PubMed ID: 31586229
[TBL] [Abstract][Full Text] [Related]
13. Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses.
Takiar V; Garden AS; Ma D; Morrison WH; Edson M; Zafereo ME; Gunn GB; Fuller CD; Beadle B; Frank SJ; William WN; Kies M; El-Naggar AK; Weber R; Rosenthal DI; Phan J
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1117-31. PubMed ID: 27354127
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
16. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.
Foy JP; Bazire L; Ortiz-Cuaran S; Deneuve S; Kielbassa J; Thomas E; Viari A; Puisieux A; Goudot P; Bertolus C; Foray N; Kirova Y; Verrelle P; Saintigny P
BMC Med; 2017 Sep; 15(1):165. PubMed ID: 28859688
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results.
Ghosh-Laskar S; Yathiraj PH; Dutta D; Rangarajan V; Purandare N; Gupta T; Budrukkar A; Murthy V; Kannan S; Agarwal JP
Head Neck; 2016 Apr; 38 Suppl 1():E1481-7. PubMed ID: 26561342
[TBL] [Abstract][Full Text] [Related]
18. Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate.
Strojan P; Corry J; Eisbruch A; Vermorken JB; Mendenhall WM; Lee AW; Haigentz M; Beitler JJ; de Bree R; Takes RP; Paleri V; Kelly CG; Genden EM; Bradford CR; Harrison LB; Rinaldo A; Ferlito A
Head Neck; 2015 Jan; 37(1):134-50. PubMed ID: 24481720
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
[TBL] [Abstract][Full Text] [Related]
20. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
